Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Panelists discuss how balancing survival benefits with quality of life involves careful monitoring of treatment-related adverse effects. Managing immune-related adverse events in patients on immune checkpoint inhibitors like cemiplimab requires early detection, timely intervention and proactive strategies to minimize impact on outcomes.
Panelists discuss how subgroup analyses of the EMPOWER-Lung 1 study assessed the efficacy of pembrolizumab across various patient groups, including those with different PD-L1 expression levels, tumor histology and prior therapies. Results demonstrated consistent survival benefits, highlighting pembrolizumab’s broad clinical applicability in advanced non-small cell lung cancer (NSCLC).
A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along with improved outcomes.
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for Bizengri (zenocutuzumab) as a promising treatment option.
Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
The study authors say their findings argue for careful reading of CT scans done for other reasons that may reveal the presence of lung nodules.
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more recent diagnosis and prior glucocorticoid/steroid use.
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with non-small cell lung cancer.
Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ancestry, and a 45% higher risk in a broader group.
Native Americans face the longest travel times, even after accounting for distances in rural areas, according to results of a recently published cross-sectional study. Lowering transportation barriers could increase screening and early detection.
But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.
By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer benefits that previous trials overlooked.
The risk for lung cancer is especially high among those with rheumatoid arthritis who also have interstitial lung disease.
Patients and their caregivers might benefit from being aware of the stigma to advocate for compassionate, optimal care.
